• Media Centre
  • Investor relations
  • Client area
  • Client area
  • Stewardship policy
  • Annual reports service

Form of Proxy

IOVANCE BIOTHERAPEUTICS, INC.

Notes

No. Proposition For Against Abstain
1

DIRECTOR Iain Dukes, D. Phil.

2

DIRECTOR Athena Countouriotis MD

3

DIRECTOR Ryan Maynard

4

DIRECTOR Wayne P. Rothbaum

5

DIRECTOR F. G. Vogt, Ph.D., J.D.

6

DIRECTOR Michael Weiser, MD, PhD

7

To approve, by non-binding advisory vote, the compensation of our named executive officers.

8

To approve, by non-binding advisory vote, the frequency of our future votes on the compensation of our named executive officers.

9

To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.

10

To approve an amendment to our 2020 Employee Stock Purchase Plan to increase the number of shares of the Companys common stock authorized for issuance thereunder by 1,000,000 shares.

11

To approve an amendment to our Certificate of Incorporation, as amended, to increase the number of authorized shares of the Companys common stock from 500,000,000 shares to 650,000,000 shares.

12

To approve an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal 6.